Brain scan study of Cobenfy in schizophrenia
Treatments studied
Part of Mental health clinical trials.
This study tests a new medication called Cobenfy (also known as trospium) using brain scans to see how it affects dopamine in people with schizophrenia. If you have schizophrenia and are not currently on antipsychotics, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You have schizophrenia, schizoaffective disorder, or schizophreniform disorder.
- You are not currently taking any antipsychotic medication and have been off it for at least 3 weeks (4 weeks for certain meds).
- Your symptoms are moderate (not too mild, not too severe).
- You are willing to use effective birth control if you're a woman who could become pregnant.
- You have not used nicotine (cigarettes, vaping, etc.) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special brain scan (PET) to measure cannabinoid receptors—areas in the brain that interact with cannabis-like chemicals. It may help researchers better understand how these receptors relate to conditions such as schizophrenia, PTSD, opioid use disorder, or early psychosis risk.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This study tests whether a medication called Cobenfy can reduce cocaine's effects in people with cocaine use disorder. Researchers will monitor your health and test how the medication impacts your response to cocaine.
This early (Phase 1) study uses a special brain scan to look at synapses—the contact points between brain cells—in people with schizophrenia-related conditions. It helps researchers understand brain activity and connection patterns, which may guide future tests or treatments.
This study uses special PET brain scans to see how a new experimental antipsychotic medication (SIPI6398) attaches to dopamine receptors in the brain. Researchers want to understand how the medication works and if it might help people with schizophrenia.
This study tests whether a medication called COBENFY (trospium chloride) can improve memory and brain wave activity in adults with epilepsy who are already scheduled for brain surgery with electrodes. It aims to see if enhancing a brain chemical called acetylcholine helps with memory and seizure focus.
Hear when a new SCHIZOPHRENIA 1 (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.